Citation Impact
Citing Papers
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
2013 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
Restaging laparotomy in the management of the non‐Hodgkin lymphomas
1982
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
Clinical trials in primary hepatocellular carcinoma: current status and future directions
1988
Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma.
1989 StandoutNobel
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Regimen-related toxicity in patients undergoing bone marrow transplantation.
1988 StandoutNobel
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1996 Standout
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
2003 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Review: The treatment and prevention of obesity: a systematic review of the literature
1997
A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma
2008 Standout
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
1991
Management of Hepatocellular Carcinoma *
2005 Standout
What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions
2004
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
2001 Standout
Coping styles in animals: current status in behavior and stress-physiology
1999 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Cardiotoxicity of Chemotherapeutic Agents
2000
Treatment of Cutaneous T Cell Lymphoma
2002
Congestive heart failure in patients treated with doxorubicin
2003 Standout
Patterns of Relapse in 1001 Consecutive Patients With Melanoma Nodal Metastases
1989
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.
1998 Standout
Sézary syndrome: Diagnosis, prognosis, and critical review of treatment options
1990
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
Evaluating the public health impact of health promotion interventions: the RE-AIM framework.
1999 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
1991 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Obesity in children and young people: a crisis in public health
2004 Standout
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.
1993
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Chemotherapy for advanced hepatocellular carcinoma Adriamycin versus quadruple chemotherapy
1984
Doxorubicin (adriamycin) cardiomyopathy.
1983
Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications
2015 StandoutNobel
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
2013 Standout
Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy
1987 Standout
Treatment of Cutaneous T-Cell Lymphoma
1985
Cutaneous T Cell Lymphoma
1986
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
2001 Standout
Combination chemotherapy of refractory lymphoma with cis-dichlorodiamineplatinum, vinblastine, and bleomycin
1982
Pharmacological and surgical treatment of obesity.
2004
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.
1997 Standout
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
1979 Standout
Stretchable and Soft Electronics using Liquid Metals
2017 Standout
Efficacy and effectiveness trials (and other phases of research) in the development of health promotion programs
1986
Photochemotherapy for cutaneous T cell lymphoma
1984
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
1985
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
1988
Why Don’t We See More Translation of Health Promotion Research to Practice? Rethinking the Efficacy-to-Effectiveness Transition
2003 Standout
Cardiotoxicity of Cancer Therapy
2005
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
2001 Standout
Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen
1993
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities
1983
Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphoma.
1983 StandoutNobel
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Small-Cell Carcinoma of Lung: Reinduction Therapy After Late Relapse
1983
The Anthracycline Antineoplastic Drugs
1981 Standout
Behavioural, physiological and immunological consequences of social status and aggression in chronically coexisting resident-intruder dyads of male rats
1986
Mechanisms of Therapeutic Activity for Gallium
1998
Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B
1981
Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (hac) vs. cisplatin, adriamycin, cyclophosphamide (pac) in advanced ovarian cancer: long-term results
1991
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
1999 Standout
Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial
2009
Cisplatin
1984 Standout
Cardiovascular Complications of Cancer Therapy
2004
Works of Jones Se being referenced
Studies on responses by 'resident' rats housed in different ways to intruders of differing endocrine status [proceedings].
1979
Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study.
1979
Noninvasive cardiac evaluation of patients receiving adriamycin.
1978
Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group.
1977
1-year followup of cardiac status after adriamycin therapy.
1980
Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
1977
Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial.
1976
"Current status of adjuvant therapy".
1975
Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study.
1980
Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study.
1983
Myocardial infarction in a 27-year-old woman: possible complication of treatemtn with VP-16-213 (NSC-141540), mediastinal irradiation, or both.
1976
Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors.
1981
Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy.
1980
Surgical restaging of Hodgkin's disease.
1982
Does behaviour therapy work for dietitians? An experimental evaluation of the effects of three procedures in a weight reduction clinic.
1986
How to evaluate improvements in cancer treatment: the debate continues.
1978